Leading the way in corneal therapy

Claris works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision making

the SCOPE

Claris is pioneering solutions for patient populations struggling with sight-threatening corneal diseases

An Estimated

12,500,000

people are affected by corneal diseases worldwide1

Corneal therapy
  • Neurotrophic keratitis
  • Persistent corneal defect
  • Corneal ulcer
  • Dry eye disease
  • Microbial keratitis
  • Bacterial keratitis
  • Chemical burn
  • Thermal burn
  • Mechanical trauma
  • Fuch’s corneal dystrophy
  • Corneal scar
  • Sjögren's syndrome
  • Corneal edema

    • THE OBJECTIVE

    Claris is synonymous with robust science and data-driven decision making. Our goal: Improving the lives of patients with corneal disease. Claris is developing recombinant human deleted hepatocyte growth factor (dHGF) to accelerate and improve the quality of corneal healing.

    Patients first

    Patient-Focused Products

    • Validated unmet medical needs
    • Novel mechanisms of action
    • Patient-friendly dosing, storage, and handling
    Transformative

    Breakthrough Therapy

    • Accelerate healing following injury
    • Reduce scarring in mechanical and bacterial injury models
    • Reverse recent and long-term scarring induced by injury model
    • Improve visual outcomes
    Scientific rigor

    Rigorous Scientific Rationale

    • Epitheliotropic
    • Anti-fibrotic
    • Neurotrophic
    • Anti-inflammatory